# A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

> **NCT05208125** · PHASE1 · COMPLETED · sponsor: **IrsiCaixa** · enrollment: 30 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
- **OTHER:** Normal saline solution

## Key facts

- **NCT ID:** NCT05208125
- **Lead sponsor:** IrsiCaixa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-30
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-12-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208125, "A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05208125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*